178 related articles for article (PubMed ID: 27316377)
1. Nek2 siRNA therapy using a portal venous port-catheter system for liver metastasis in pancreatic cancer.
Kokuryo T; Hibino S; Suzuki K; Watanabe K; Yokoyama Y; Nagino M; Senga T; Hamaguchi M
Cancer Sci; 2016 Sep; 107(9):1315-20. PubMed ID: 27316377
[TBL] [Abstract][Full Text] [Related]
2. Nek2 as an effective target for inhibition of tumorigenic growth and peritoneal dissemination of cholangiocarcinoma.
Kokuryo T; Senga T; Yokoyama Y; Nagino M; Nimura Y; Hamaguchi M
Cancer Res; 2007 Oct; 67(20):9637-42. PubMed ID: 17942892
[TBL] [Abstract][Full Text] [Related]
3. Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin.
Suzuki K; Kokuryo T; Senga T; Yokoyama Y; Nagino M; Hamaguchi M
Cancer Sci; 2010 May; 101(5):1163-9. PubMed ID: 20345485
[TBL] [Abstract][Full Text] [Related]
4. Hepatoma cell functions modulated by NEK2 are associated with liver cancer progression.
Wu SM; Lin SL; Lee KY; Chuang HC; Feng PH; Cheng WL; Liao CJ; Chi HC; Lin YH; Tsai CY; Chen WJ; Yeh CT; Lin KH
Int J Cancer; 2017 Apr; 140(7):1581-1596. PubMed ID: 27925179
[TBL] [Abstract][Full Text] [Related]
5. Systemic Administration of Small Interfering RNA Targeting Human Nestin Inhibits Pancreatic Cancer Cell Proliferation and Metastasis.
Matsuda Y; Ishiwata T; Yoshimura H; Yamashita S; Ushijima T; Arai T
Pancreas; 2016 Jan; 45(1):93-100. PubMed ID: 26335012
[TBL] [Abstract][Full Text] [Related]
6. Nek2 as a novel molecular target for the treatment of breast carcinoma.
Tsunoda N; Kokuryo T; Oda K; Senga T; Yokoyama Y; Nagino M; Nimura Y; Hamaguchi M
Cancer Sci; 2009 Jan; 100(1):111-6. PubMed ID: 19038001
[TBL] [Abstract][Full Text] [Related]
7. Lentivirus-mediated shRNA interference targeting vascular endothelial growth factor inhibits angiogenesis and progression of human pancreatic carcinoma.
Zhao X; Zhu DM; Gan WJ; Li Z; Zhang JL; Zhao H; Zhou J; Li DC
Oncol Rep; 2013 Mar; 29(3):1019-26. PubMed ID: 23254994
[TBL] [Abstract][Full Text] [Related]
8. CD110 promotes pancreatic cancer progression and its expression is correlated with poor prognosis.
Yan Z; Ohuchida K; Zheng B; Okumura T; Takesue S; Nakayama H; Iwamoto C; Shindo K; Moriyama T; Nakata K; Miyasaka Y; Ohtsuka T; Mizumoto K; Oda Y; Hashizume M; Nakamura M
J Cancer Res Clin Oncol; 2019 May; 145(5):1147-1164. PubMed ID: 30770989
[TBL] [Abstract][Full Text] [Related]
9. Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple‑negative breast cancer cells.
Lee J; Gollahon L
Int J Oncol; 2013 Mar; 42(3):839-47. PubMed ID: 23340795
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation of NEK2 by microRNA-128 methylation is associated with poor prognosis in colorectal cancer.
Takahashi Y; Iwaya T; Sawada G; Kurashige J; Matsumura T; Uchi R; Ueo H; Takano Y; Eguchi H; Sudo T; Sugimachi K; Yamamoto H; Doki Y; Mori M; Mimori K
Ann Surg Oncol; 2014 Jan; 21(1):205-12. PubMed ID: 24046120
[TBL] [Abstract][Full Text] [Related]
11. PLGA/poloxamer nanoparticles loaded with EPAS1 siRNA for the treatment of pancreatic cancer in vitro and in vivo.
Pan X; Zhu Q; Sun Y; Li L; Zhu Y; Zhao Z; Zuo J; Fang W; Li K
Int J Mol Med; 2015 Apr; 35(4):995-1002. PubMed ID: 25672594
[TBL] [Abstract][Full Text] [Related]
12. Gold nanoclusters-assisted delivery of NGF siRNA for effective treatment of pancreatic cancer.
Lei Y; Tang L; Xie Y; Xianyu Y; Zhang L; Wang P; Hamada Y; Jiang K; Zheng W; Jiang X
Nat Commun; 2017 Apr; 8():15130. PubMed ID: 28440296
[TBL] [Abstract][Full Text] [Related]
13. NEK2 Is an Effective Target for Cancer Therapy With Potential to Induce Regression of Multiple Human Malignancies.
Kokuryo T; Yokoyama Y; Yamaguchi J; Tsunoda N; Ebata T; Nagino M
Anticancer Res; 2019 May; 39(5):2251-2258. PubMed ID: 31092416
[TBL] [Abstract][Full Text] [Related]
14. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1.
Zhang X; Huang X; Xu J; Li E; Lao M; Tang T; Zhang G; Guo C; Zhang X; Chen W; Yadav DK; Bai X; Liang T
Nat Commun; 2021 Jul; 12(1):4536. PubMed ID: 34315872
[TBL] [Abstract][Full Text] [Related]
15. A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene expression.
Zhao X; Li DC; Zhao H; Li Z; Wang JX; Zhu DM; Zhou J; Cen JN
Oncol Rep; 2012 Mar; 27(3):628-36. PubMed ID: 22200682
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer.
Zeng YR; Han ZD; Wang C; Cai C; Huang YQ; Luo HW; Liu ZZ; Zhuo YJ; Dai QS; Zhao HB; Liang YX; Zhong WD
BMC Urol; 2015 Aug; 15():90. PubMed ID: 26320076
[TBL] [Abstract][Full Text] [Related]
17. The Nek2 centrosome-mitotic kinase contributes to the mesenchymal state, cell invasion, and migration of triple-negative breast cancer cells.
Rivera-Rivera Y; Marina M; Jusino S; Lee M; Velázquez JV; Chardón-Colón C; Vargas G; Padmanabhan J; Chellappan SP; Saavedra HI
Sci Rep; 2021 Apr; 11(1):9016. PubMed ID: 33907253
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors.
Wang J; Lu Z; Wang J; Cui M; Yeung BZ; Cole DJ; Wientjes MG; Au JL
J Control Release; 2015 Oct; 216():103-10. PubMed ID: 26272765
[TBL] [Abstract][Full Text] [Related]
19. Increased NEK2 in hepatocellular carcinoma promotes cancer progression and drug resistance by promoting PP1/Akt and Wnt activation.
Wen S; Liu Y; Yang M; Yang K; Huang J; Feng D
Oncol Rep; 2016 Oct; 36(4):2193-9. PubMed ID: 27509921
[TBL] [Abstract][Full Text] [Related]
20. CGK062, a small chemical molecule, inhibits cancer upregulated gene 2‑induced oncogenesis through NEK2 and β‑catenin.
Kaowinn S; Oh S; Moon J; Yoo AY; Kang HY; Lee MR; Kim JE; Hwang DY; Youn SE; Koh SS; Chung YH
Int J Oncol; 2019 Apr; 54(4):1295-1305. PubMed ID: 30968157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
